Liu, Chen-Hua http://orcid.org/0000-0003-3622-9707
Peng, Cheng-Yuan http://orcid.org/0000-0001-9030-6086
Fang, Yu-Jen
Kao, Wei-Yu http://orcid.org/0000-0002-5506-4293
Yang, Sheng-Shun
Lin, Cheng-Kuan
Lai, Hsueh-Chou
Su, Wen-Pang
Fang, Sheng-Uei
Chang, Chun-Chao
Su, Tung-Hung http://orcid.org/0000-0002-6747-7941
Liu, Chun-Jen http://orcid.org/0000-0001-8082-7144
Chen, Pei-Jer
Chen, Ding-Shinn
Kao, Jia-Horng http://orcid.org/0000-0002-2442-7952
Funding for this research was provided by:
Merck & Co., Inc. | Merck Sharp and Dohme (MISP 55746)
Article History
Received: 22 January 2020
Accepted: 12 May 2020
First Online: 8 June 2020
Competing interests
: Dr. Chen-Hua Liu has received compensations as a member of the scientific advisory board for Abbvie and Gilead Sciences. He has consulted for Abbott, AbbVie, Gilead Sciences, and Merck Sharp & Dohme, and received compensations. He also has received research grants from Abbvie, Gilead Sciences, and Merck Sharp & Dohme. Dr. Chun-Jen Liu has received compensations as a member of the scientific advisory board for Gilead Sciences and Merck Sharp & Dohme. He has consulted for AbbVie, Gilead Sciences, and Merck Sharp & Dohme, and received compensations. He also has received research grant from Gilead Sciences. Dr. Jia-Horng Kao has received compensations as a member of the scientific advisory board for Abbott, AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche. He has consulted for Abbott, AbbVie, Bayer, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Roche and received compensations. Dr. Ding-Shinn Chen has received compensations as a member of the scientific advisory board for Abbvie, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, and Novartis. Dr. Pei-Jer Chen has received compensations as a member of the scientific advisory board for AbbVie, Novartis, and Roche. All other authors declare no potential conflict of interest.